{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:22:15Z","timestamp":1791264135681,"version":"4.1.0"},"reference-count":40,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The genetics of acute lymphoblastic leukemia are becoming well understood and the incidence of individual chromosomal abnormalities varies considerably with age. Cytogenetics provide reliable risk stratification for treatment: high hyperdiploidy and ETV6-RUNX1 are good risk, whereas BCR-ABL1, MLL rearrangements, and hypodiploidy are poor risk. Nevertheless, some patients within the good- and intermediate-risk groups will unpredictably relapse. With advancing technologies in array-based approaches (single nucleotide polymorphism arrays) and next-generation sequencing to study the genome, increasing numbers of new genetic changes are being discovered. These include deletions of B-cell differentiation and cell cycle control genes, as well as mutations of genes in key signaling pathways. Their associations and interactions with established cytogenetic subgroups and with each other are becoming elucidated. Whether they have a link to outcome is the most important factor for refinement of risk factors in relation to clinical trials. For several newly identified abnormalities, including intrachromosomal amplification of chromosome 21 (iAMP21), that are associated with a poor prognosis with standard therapy, appropriately modified treatment has significantly improved outcome. After the successful use of tyrosine kinase inhibitors in the treatment of BCR-ABL1\u2013positive acute lymphoblastic leukemia, patients with alternative ABL1 translocations and rearrangements involving PDGFRB may benefit from treatment with tyrosine kinase inhibitors. Other aberrations, for example, CRLF2 overexpression and JAK2 mutations, are also providing potential novel therapeutic targets with the prospect of reduced toxicity.<\/jats:p>","DOI":"10.1182\/asheducation-2013.1.118","type":"journal-article","created":{"date-parts":[[2013,12,6]],"date-time":"2013-12-06T10:51:13Z","timestamp":1386327073000},"page":"118-125","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":41,"title":["Targeting signaling pathways in acute lymphoblastic leukemia: new insights"],"prefix":"10.1182","volume":"2013","author":[{"given":"Christine J.","family":"Harrison","sequence":"first","affiliation":[{"name":"Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"6","key":"2019111704332704300_B1","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood-2012-05-378943","article-title":"Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?","volume":"120","author":"Pui","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2019111704332704300_B2","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/MOH.0b013e3283034697","article-title":"Progress in the treatment of adults with acute lymphoblastic leukemia","volume":"15","author":"Larson","year":"2008","journal-title":"Curr Opin Hematol"},{"issue":"5","key":"2019111704332704300_B3","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S1470-2045(10)70066-8","article-title":"Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97\/99 randomised trial","volume":"11","author":"Moorman","year":"2010","journal-title":"Lancet Oncol"},{"issue":"25","key":"2019111704332704300_B4","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1200\/JCO.2011.40.3907","article-title":"IGH@ translocations, CRLF2 deregulation and micro-deletions in adolescents and adults with acute lymphoblastic leukemia (ALL)","volume":"30","author":"Moorman","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111704332704300_B5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.blre.2012.01.001","article-title":"The clinical relevance of chromosomal and genomic abnormalities in B-cell precursor acute lymphoblastic leukaemia","volume":"26","author":"Moorman","year":"2012","journal-title":"Blood Rev"},{"issue":"25","key":"2019111704332704300_B6","doi-asserted-by":"crossref","first-page":"6848","DOI":"10.1182\/blood-2011-01-329961","article-title":"Genomic characterization implicates iAMP21 as a likely primary genetic event in childhood B-cell precursor acute lymphoblastic leukemia","volume":"117","author":"Rand","year":"2011","journal-title":"Blood"},{"issue":"27","key":"2019111704332704300_B7","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1200\/JCO.2013.48.9377","article-title":"Risk-directed treatment intensification significantly reduces the risk of relapse among children and adolescents with acute lymphoblastic leukemia and intrachromosomal amplification of chromosome 21: a comparison of the MRC ALL97\/99 and UKALL2003 trials","volume":"31","author":"Moorman","year":"2013","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111704332704300_B8","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1182\/blood-2009-09-235986","article-title":"Immunoglobulin heavy chain locus chromosomal translocations in B-cell precursor acute lymphoblastic leukemia: rare clinical curios or potent genetic drivers?","volume":"115","author":"Dyer","year":"2010","journal-title":"Blood"},{"issue":"7","key":"2019111704332704300_B9","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1182\/blood-2010-07-297135","article-title":"Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial","volume":"117","author":"Ensor","year":"2011","journal-title":"Blood"},{"issue":"13","key":"2019111704332704300_B10","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1182\/blood-2009-03-208397","article-title":"Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia","volume":"114","author":"Russell","year":"2009","journal-title":"Blood"},{"issue":"11","key":"2019111704332704300_B11","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/ng.469","article-title":"Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia","volume":"41","author":"Mullighan","year":"2009","journal-title":"Nat Genet"},{"issue":"3","key":"2019111704332704300_B12","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/leu.2009.231","article-title":"Activating mutation in the TSLPR gene in B-cell precursor lymphoblastic leukemia","volume":"24","author":"Chapiro","year":"2010","journal-title":"Leukemia"},{"issue":"26","key":"2019111704332704300_B13","doi-asserted-by":"crossref","first-page":"5393","DOI":"10.1182\/blood-2009-11-256131","article-title":"Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol","volume":"115","author":"Cario","year":"2010","journal-title":"Blood"},{"issue":"5","key":"2019111704332704300_B14","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1056\/NEJMoa0808253","article-title":"Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia","volume":"360","author":"Mullighan","year":"2009","journal-title":"N Engl J Med"},{"issue":"7137","key":"2019111704332704300_B15","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/nature05690","article-title":"Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia","volume":"446","author":"Mullighan","year":"2007","journal-title":"Nature"},{"issue":"6","key":"2019111704332704300_B16","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1038\/sj.leu.2404691","article-title":"High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression","volume":"21","author":"Kuiper","year":"2007","journal-title":"Leukemia"},{"issue":"11","key":"2019111704332704300_B17","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1182\/blood-2011-03-341412","article-title":"Key pathways are frequently mutated in high risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group","volume":"118","author":"Zhang","year":"2011","journal-title":"Blood"},{"issue":"23","key":"2019111704332704300_B18","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1200\/JCO.2011.34.8144","article-title":"Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia","volume":"29","author":"Hof","year":"2011","journal-title":"J Clin Oncol"},{"issue":"7337","key":"2019111704332704300_B19","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature09727","article-title":"CREBBP mutations in relapsed acute lymphoblastic leukaemia","volume":"471","author":"Mullighan","year":"2011","journal-title":"Nature"},{"issue":"8","key":"2019111704332704300_B20","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/leu.2012.60","article-title":"CREBBP HAT domain mutations prevail in relapse cases of high hyperdiploid childhood acute lymphoblastic leukemia","volume":"26","author":"Inthal","year":"2012","journal-title":"Leukemia"},{"issue":"3","key":"2019111704332704300_B21","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/ng.2558","article-title":"Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia","volume":"45","author":"Meyer","year":"2013","journal-title":"Nat Genet"},{"issue":"7","key":"2019111704332704300_B22","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.3324\/haematol.2013.085175","article-title":"Genes commonly deleted in childhood B-cell precursor acute lymphoblastic leukemia: association with cytogenetics and clinical features","volume":"98","author":"Schwab","year":"2013","journal-title":"Haematologica"},{"issue":"6","key":"2019111704332704300_B23","doi-asserted-by":"crossref","first-page":"937","DOI":"10.3324\/haematol.2012.067983","article-title":"Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants","volume":"98","author":"Driessen","year":"2013","journal-title":"Haematologica"},{"issue":"16","key":"2019111704332704300_B24","doi-asserted-by":"crossref","first-page":"6803","DOI":"10.1158\/0008-5472.CAN-08-0101","article-title":"Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia","volume":"68","author":"Case","year":"2008","journal-title":"Cancer Res"},{"issue":"1","key":"2019111704332704300_B25","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/gcc.20502","article-title":"Mutations of FLT3, NRAS, KRAS, and PTPN11 are frequent and possibly mutually exclusive in high hyperdiploid childhood acute lymphoblastic leukemia","volume":"47","author":"Paulsson","year":"2008","journal-title":"Genes Chromosomes Cancer"},{"issue":"3","key":"2019111704332704300_B26","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/ng.2532","article-title":"The genomic landscape of hypodiploid acute lymphoblastic leukemia","volume":"45","author":"Holmfeldt","year":"2013","journal-title":"Nat Genet"},{"issue":"26","key":"2019111704332704300_B27","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1182\/blood-2009-09-245944","article-title":"Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic\/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia","volume":"115","author":"Harvey","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2019111704332704300_B28","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1470-2045(08)70339-5","article-title":"A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study","volume":"10","author":"Den Boer","year":"2009","journal-title":"Lancet Oncol"},{"issue":"23","key":"2019111704332704300_B29","doi-asserted-by":"crossref","first-page":"4874","DOI":"10.1182\/blood-2009-08-239681","article-title":"Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome","volume":"116","author":"Harvey","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2019111704332704300_B30","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ccr.2012.06.005","article-title":"Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia","volume":"22","author":"Roberts","year":"2012","journal-title":"Cancer Cell"},{"issue":"13","key":"2019111704332704300_B31","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1182\/blood-2008-07-077958","article-title":"Translation of the Philadelphia chromosome into therapy for CML","volume":"112","author":"Druker","year":"2008","journal-title":"Blood"},{"issue":"31","key":"2019111704332704300_B32","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1200\/JCO.2008.21.2514","article-title":"Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study","volume":"27","author":"Schultz","year":"2009","journal-title":"J Clin Oncol"},{"key":"2019111704332704300_B33","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/asheducation-2009.1.371","article-title":"Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)","volume":"2009","author":"Ottmann","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"22","key":"2019111704332704300_B34","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1182\/blood-2012-09-456517","article-title":"Episomal amplification of NUP214-ABL1 fusion gene in B-cell acute lymphoblastic leukemia","volume":"120","author":"Eyre","year":"2012","journal-title":"Blood"},{"issue":"25","key":"2019111704332704300_B35","doi-asserted-by":"crossref","first-page":"e413","DOI":"10.1200\/JCO.2012.47.6770","article-title":"Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB positive acute lymphoblastic leukemia","volume":"31","author":"Weston","year":"2013","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111704332704300_B36","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1182\/blood-2011-12-389932","article-title":"Aberrant STAT5 and PI3K\/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia","volume":"120","author":"Tasian","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2019111704332704300_B37","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ccr.2011.06.009","article-title":"Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor","volume":"20","author":"Daigle","year":"2011","journal-title":"Cancer Cell"},{"issue":"8","key":"2019111704332704300_B38","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1182\/blood-2011-10-382861","article-title":"Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study","volume":"119","author":"Kang","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2019111704332704300_B39","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3324\/haematol.2012.073965","article-title":"Breakpoint-specific multiplex polymerase chain reaction allows the detection of IKZF1 intragenic deletions and minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia","volume":"98","author":"Caye","year":"2013","journal-title":"Haematologica"},{"issue":"7330","key":"2019111704332704300_B40","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/nature09650","article-title":"Genetic variegation of clonal architecture and propagating cells in leukaemia","volume":"469","author":"Anderson","year":"2011","journal-title":"Nature"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2013\/1\/118\/1250024\/bep00113000118.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2013\/1\/118\/1250024\/bep00113000118.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T04:33:46Z","timestamp":1573965226000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2013\/1\/118\/20784\/Targeting-signaling-pathways-in-acute"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,6]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2013.1.118","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,6]]}}}